

REMARKS/ARGUMENTS

Claims 4-10 have been withdrawn because of a restriction requirement. Applicants reserve their right to file a divisional application(s) directed to non-elected material that has been withdrawn because of the restriction requirement.

The Examiner has required restriction in the above-identified application and has divided the claims as follows:

- Group I: Claims 1-3 are drawn to a method of identifying a substance suitable for use in the treatment of leukocyte-associated inflammatory disease which modulates the activity of a polypeptide encoded by human transient receptor potential 6 gene (TRPC6) comprising combining a candidate substance with said polypeptide and measuring the effects of the candidate substance on the activity of said polypeptide classified in class 514, subclass 2.
- Group II: Claims 4-5 are drawn to a pharmaceutical composition comprising a compound that inhibits the influx of calcium ions through human TRPC6 ion channel and a pharmaceutical acceptable carrier, classified in class 514, subclass 2.
- Group III: Claims 6-9 are drawn to a method of treating a leukocyte-associated inflammatory disease comprising administering to said subject an effective amount of an antibody which is immunoreactive with a polypeptide encoded by human (TRPC6) or an antisense oligonucleotide comprising a nucleotide sequence encoding that polypeptide classified in class 514, subclass 2.
- Group IV: Claim 10 is drawn to a method of treating pulmonary hypertension in a subject in need of such treatment which comprises administering to said subject an effective amount of a TRPC6 inhibitor classified in class 514, subclass 2.

Without traverse Applicants elect Group I.

The Examiner indicates that Applicant is required under 35 U.S.C. 121 to elect a species. The disease elected for examination purposes is COPD.

In view of the remarks and the amendments, further and favorable consideration of the present application and the allowance of all pending claims are respectfully requested. The Examiner is also invited to contact the undersigned should the Examiner believe that such contact would expedite prosecution of the present application.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-2614



Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Date: 3/5/07